LifeStance Health Group, Inc. (LFST)
NASDAQ: LFST · Real-Time Price · USD
14.08
-0.07 (-0.49%)
At close: Nov 13, 2026, 4:00 PM EST
13.67
-0.41 (-2.89%)
After-hours: Nov 13, 2026, 7:30 PM EST
LifeStance Health Group Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, LifeStance Health Group stock has a consensus rating of "Buy" and an average price target of $16.8. The average 1-year stock price forecast is 19.32% higher than the current stock price, while the lowest is $12 (-14.77%) and the highest is $20 (+42.05%).
Price Target: $16.8 (+19.32%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for LifeStance Health Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Hold Maintains $13 → $15 | Hold | Maintains | $13 → $15 | +6.53% | Nov 12, 2026 |
| Barclays | Barclays | Buy Reiterates $15 → $18 | Buy | Reiterates | $15 → $18 | +27.84% | Nov 11, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Maintains $15 → $19 | Buy | Maintains | $15 → $19 | +34.94% | Nov 9, 2026 |
| BMO Capital | BMO Capital | Buy Reiterates $13 → $16 | Buy | Reiterates | $13 → $16 | +13.64% | Nov 6, 2026 |
| BTIG | BTIG | Buy Maintains $18 → $20 | Buy | Maintains | $18 → $20 | +42.05% | Nov 6, 2026 |
Financial Forecast
Revenue This Year
1.75B
from 1.42B
Increased by 22.65%
Revenue Next Year
1.98B
from 1.75B
Increased by 13.62%
EPS This Year
0.40
from 0.18
Increased by 121.20%
EPS Next Year
0.45
from 0.40
Increased by 11.31%
EPS and Forward PE are based on non-GAAP adjusted numbers.